Eosinophilic Asthma Market Report 2026

The eosinophilic asthma market size has grown rapidly in recent years. It will grow from $3.16 billion in 2025 to $3.71 billion in 2026 at a compound annual growth rate (CAGR) of 17.4%. The growth in the historic period can be attributed to poor response to inhaled steroids, asthma prevalence growth, eosinophil biomarker identification, hospital asthma admissions, chronic respiratory disease burden.

The eosinophilic asthma market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2030 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to precision asthma treatment growth, biologic drug pipeline expansion, biomarker-based diagnosis, personalized respiratory care, specialty clinic expansion. Major trends in the forecast period include growing adoption of biologic therapies, increased focus on severe asthma phenotypes, rising demand for targeted immunotherapy, expansion of specialized respiratory clinics, emphasis on reducing exacerbation rates.

The rising prevalence of smoking habits is expected to drive the growth of the eosinophilic asthma market in the coming years. Smoking habits refer to the regular use of tobacco products, including the frequency, context, and duration of smoking, often influenced by psychological, social, and environmental factors. Factors contributing to increasing smoking habits include higher stress levels, targeted marketing by tobacco companies, lack of awareness about health risks, and social acceptance of smoking in certain cultures. Eosinophilic asthma treatments help reduce airway inflammation and improve lung function, which can support smoking cessation by alleviating respiratory symptoms that often perpetuate smoking. For example, in November 2025, the Office for National Statistics, a UK-based government agency, reported that the percentage of women using e-cigarettes in Great Britain increased from 8.5% in 2023 to 10% in 2024. Daily e-cigarette use was highest among people aged 25 to 34 years and 35 to 49 years (9.3% and 9.5%, respectively) and has increased in both age groups since 2023. Therefore, the rising smoking rates are contributing to the growth of the eosinophilic asthma market.

Key companies in the eosinophilic asthma market are developing innovative therapies that target specific immune pathways, reduce inflammation, and improve patient outcomes through personalized treatment options. Monoclonal antibodies are laboratory-made molecules designed to mimic the immune system’s ability to fight harmful pathogens. They are produced by fusing a specific antibody-producing cell with a cancer cell, enabling the generation of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, announced that Fasenra was approved by China’s National Medical Products Association for the treatment of severe eosinophilic asthma. Fasenra is indicated for patients with high levels of eosinophils, which can worsen asthma symptoms. It is a monoclonal antibody that targets and depletes eosinophils by binding to the IL-5 receptor, reducing eosinophil levels in the blood and tissues. The dosing regimen includes an initial loading phase followed by maintenance injections every four weeks for the first three doses, then every eight weeks thereafter.

In February 2024, GSK plc, a UK-based biopharmaceutical company, acquired Aiolos Bio for $1 billion. Through this acquisition, GSK aims to strengthen its respiratory portfolio by targeting severe asthma patients with low T2 inflammation, expanding its market reach, and reinforcing its leadership in respiratory therapies while addressing a broader spectrum of asthma patients. Aiolos Bio, based in the US, specializes in developing treatments for respiratory and inflammatory conditions, including eosinophilic asthma.

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol‑Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, Bayer AG, Eli Lilly and Company, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Cipla Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., UCB S.A., 4D Pharma plc, MorphoSys AG, Avalo Therapeutics Inc.

North America was the largest region in the eosinophilic asthma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eosinophilic asthma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the eosinophilic asthma market by increasing costs of imported biologic drugs, diagnostic tests, and specialty inhalation devices. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising pricing of biologics and diagnostic monitoring, impacting long-term disease control. However, they encourage domestic biologic production.

The eosinophilic asthma market research report is one of a series of new reports that provides eosinophilic asthma market statistics, including eosinophilic asthma industry global market size, regional shares, competitors with a eosinophilic asthma market share, detailed eosinophilic asthma market segments, market trends and opportunities, and any further data you may need to thrive in the eosinophilic asthma industry. This eosinophilic asthma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eosinophilic asthma is a type of asthma characterized by elevated eosinophil counts, a specific type of white blood cell, which lead to inflammation in the airways. This condition causes severe symptoms, including breathing difficulties and recurrent flare-ups, and often responds poorly to standard treatments like inhaled steroids.

The main disease types of eosinophilic asthma include severe eosinophilic asthma and mild to moderate eosinophilic asthma. Severe eosinophilic asthma is a more serious form of the disease, marked by high levels of eosinophils that contribute to airway inflammation. Treatment options include biologics, bronchodilators, corticosteroids, immunomodulators, and other therapies. These treatments are administered in hospitals, clinics, and other healthcare settings.

The eosinophilic asthma market consists of sales of mepolizuma and benralizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.